212 related articles for article (PubMed ID: 31977647)
1. Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.
Efuni E; Cytryn S; Boland P; Niewold TB; Pavlick A; Weber J; Sandigursky S
J Clin Rheumatol; 2021 Oct; 27(7):267-271. PubMed ID: 31977647
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer.
McCarter KR; Arabelovic S; Wang X; Wolfgang T; Yoshida K; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
Semin Arthritis Rheum; 2024 Feb; 64():152335. PubMed ID: 38100899
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
4. Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy.
Lusa A; Alvarez C; Saxena Beem S; Schwartz TA; Ishizawar R
BMC Rheumatol; 2022 Nov; 6(1):64. PubMed ID: 36345032
[TBL] [Abstract][Full Text] [Related]
5. Safety of immune checkpoint inhibitors in patients with preexisting autoimmune disorders.
Kumar R; Chan A; Bandikatla S; Ranjan S; Ngo P
Curr Probl Cancer; 2022 Aug; 46(4):100864. PubMed ID: 35671576
[TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Tison A; Quéré G; Misery L; Funck-Brentano E; Danlos FX; Routier E; Robert C; Loriot Y; Lambotte O; Bonniaud B; Scalbert C; Maanaoui S; Lesimple T; Martinez S; Marcq M; Chouaid C; Dubos C; Brunet-Possenti F; Stavris C; Chiche L; Beneton N; Mansard S; Guisier F; Doubre H; Skowron F; Aubin F; Zehou O; Roge C; Lambert M; Pham-Ledard A; Beylot-Barry M; Veillon R; Kramkimel N; Giacchero D; De Quatrebarbes J; Michel C; Auliac JB; Gonzales G; Decroisette C; Le Garff G; Carpiuc I; Vallerand H; Nowak E; Cornec D; Kostine M;
Arthritis Rheumatol; 2019 Dec; 71(12):2100-2111. PubMed ID: 31379105
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies.
Xie W; Huang H; Xiao S; Fan Y; Deng X; Zhang Z
Autoimmun Rev; 2020 Dec; 19(12):102687. PubMed ID: 33131688
[TBL] [Abstract][Full Text] [Related]
9. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
10. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
Front Oncol; 2022; 12():934093. PubMed ID: 35912183
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis.
Liu X; Li S; Ke L; Cui H
BMC Cancer; 2024 Apr; 24(1):490. PubMed ID: 38632528
[TBL] [Abstract][Full Text] [Related]
13. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.
Reid P; Sandigursky S; Song J; Lopez-Olivo MA; Safa H; Cytryn S; Efuni E; Buni M; Pavlick A; Krogsgaard M; Abu-Shawer O; Altan M; Weber JS; Rahma OE; Suarez-Almazor ME; Diab A; Abdel-Wahab N
Oncoimmunology; 2023; 12(1):2261264. PubMed ID: 38126033
[TBL] [Abstract][Full Text] [Related]
15. Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease.
Alexander S; Swami U; Kaur A; Gao Y; Fatima M; Ginn MM; Stein JE; Grivas P; Zakharia Y; Singh N
Ann Transl Med; 2021 Jun; 9(12):1033. PubMed ID: 34277833
[TBL] [Abstract][Full Text] [Related]
16. Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update.
Dang QM; Watanabe R; Shiomi M; Fukumoto K; Nobashi TW; Okano T; Yamada S; Hashimoto M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982715
[TBL] [Abstract][Full Text] [Related]
17. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
18. Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group.
Fountzilas E; Lampaki S; Koliou GA; Koumarianou A; Levva S; Vagionas A; Christopoulou A; Laloysis A; Psyrri A; Binas I; Mountzios G; Kentepozidis N; Kotsakis A; Saloustros E; Boutis A; Nikolaidi A; Fountzilas G; Georgoulias V; Chrysanthidis M; Kotteas E; Vo H; Tsiatas M; Res E; Linardou H; Daoussis D; Bompolaki I; Andreadou A; Papaxoinis G; Spyratos D; Gogas H; Syrigos KN; Bafaloukos D
Cancer Immunol Immunother; 2022 Feb; 71(2):327-337. PubMed ID: 34164709
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
[TBL] [Abstract][Full Text] [Related]
20. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
